{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/NBIX/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T07:59:21.422Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8762,"canonical_name":"NEUROCRINE BIOSCIENCES INC","cik":"0000914475","uei":null,"lei":null,"duns":null,"ticker":"NBIX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":63,"clinical":6},"count":69,"timeline":[{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":4367,"price_per_share":181.02,"usd_value":790514,"security_title":"Common Stock","importance":35.79051434},{"ts":"2026-07-10","kind":"sec.insider.m","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":4367,"price_per_share":106.02,"usd_value":462989,"security_title":"Common Stock","importance":15.46298934},{"ts":"2026-07-09","kind":"sec.form144","reporter":"DARIN LIPPOLDT","title":"Officer","shares":10000,"usd_value":1782400,"security_title":"Common","approx_sale_date":"2026-07-09","accession_number":"0001950047-26-006987","importance":40.35648},{"ts":"2026-07-09","kind":"sec.insider.s","reporter":"Lippoldt Darin","title":"Chief Legal Officer","shares":10000,"price_per_share":179.6014,"usd_value":1796014,"security_title":"Common Stock","importance":36.796014},{"ts":"2026-07-09","kind":"sec.insider.s","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":8433,"price_per_share":178.7187,"usd_value":1507135,"security_title":"Common Stock","importance":36.5071347971},{"ts":"2026-07-09","kind":"sec.insider.m","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":8433,"price_per_share":103.52,"usd_value":872984,"security_title":"Common Stock","importance":15.87298416},{"ts":"2026-07-09","kind":"sec.insider.m","reporter":"Lippoldt Darin","title":"Chief Legal Officer","shares":10000,"price_per_share":81.49,"usd_value":814900,"security_title":"Common Stock","importance":15.8149},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":2737,"price_per_share":178.543,"usd_value":488672,"security_title":"Common Stock","importance":35.488672191},{"ts":"2026-07-08","kind":"sec.insider.m","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":2737,"price_per_share":103.52,"usd_value":283334,"security_title":"Common Stock","importance":15.28333424},{"ts":"2026-07-07","kind":"sec.form144","reporter":"INGRID DELAET","title":"Officer","shares":14571,"usd_value":2536811,"security_title":"Common","approx_sale_date":"2026-07-07","accession_number":"0001950047-26-006922","importance":40.50736222},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":3401,"price_per_share":178.5666,"usd_value":607305,"security_title":"Common Stock","importance":35.6073050066},{"ts":"2026-07-07","kind":"sec.insider.m","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":3401,"price_per_share":103.52,"usd_value":352072,"security_title":"Common Stock","importance":15.352071519999999},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — Lippoldt Darin — 2026-06-30","url_slug":"/sec/cik-0001504783/4/0001504783-26-000015","accession_number":"0001504783-26-000015","importance":30},{"ts":"2026-06-29","kind":"sec.form144","reporter":"DARIN LIPPOLDT","title":"Officer","shares":9800,"usd_value":1651496,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001950047-26-006604","importance":40.3302992},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Lippoldt Darin","title":"Chief Legal Officer","shares":8110,"price_per_share":170.025,"usd_value":1378903,"security_title":"Common Stock","importance":36.37890275},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Lippoldt Darin","title":"Chief Legal Officer","shares":1690,"price_per_share":170.8144,"usd_value":288676,"security_title":"Common Stock","importance":35.288676336},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Lippoldt Darin","title":"Chief Legal Officer","shares":8110,"price_per_share":81.49,"usd_value":660884,"security_title":"Common Stock","importance":15.6608839},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Lippoldt Darin","title":"Chief Legal Officer","shares":1690,"price_per_share":81.49,"usd_value":137718,"security_title":"Common Stock","importance":15.1377181},{"ts":"2026-06-26","kind":"sec.form144","reporter":"DARIN LIPPOLDT","title":"Officer","shares":200,"usd_value":32836,"security_title":"Common","approx_sale_date":"2026-06-26","accession_number":"0001950047-26-006541","importance":40.0065672},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Lippoldt Darin","title":"Chief Legal Officer","shares":200,"price_per_share":169.565,"usd_value":33913,"security_title":"Common Stock","importance":35.033913},{"ts":"2026-06-26","kind":"sec.insider.m","reporter":"Lippoldt Darin","title":"Chief Legal Officer","shares":200,"price_per_share":81.49,"usd_value":16298,"security_title":"Common Stock","importance":15.016298},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Norwalk Leslie V — 2026-06-08","url_slug":"/sec/cik-0001533568/4/0001533568-26-000009","accession_number":"0001533568-26-000009","importance":30},{"ts":"2026-06-05","kind":"sec.form144","reporter":"STEPHEN SHERWIN","title":"Director","shares":25000,"usd_value":4183750,"security_title":"Common","approx_sale_date":"2026-06-05","accession_number":"0001950047-26-005707","importance":40.83675},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"SHERWIN STEPHEN A","title":null,"shares":7883,"price_per_share":163.807,"usd_value":1291291,"security_title":"Common Stock","importance":36.291290581},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"SHERWIN STEPHEN A","title":null,"shares":6896,"price_per_share":165.7926,"usd_value":1143306,"security_title":"Common Stock","importance":36.1433057696},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"SHERWIN STEPHEN A","title":null,"shares":5829,"price_per_share":166.5567,"usd_value":970859,"security_title":"Common Stock","importance":35.9708590043},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"SHERWIN STEPHEN A","title":null,"shares":2549,"price_per_share":164.4394,"usd_value":419156,"security_title":"Common Stock","importance":35.4191560306},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"SHERWIN STEPHEN A","title":null,"shares":1843,"price_per_share":167.3128,"usd_value":308357,"security_title":"Common Stock","importance":35.3083574904},{"ts":"2026-06-05","kind":"sec.insider.m","reporter":"SHERWIN STEPHEN A","title":null,"shares":15000,"price_per_share":53.64,"usd_value":804600,"security_title":"Common Stock","importance":15.8046},{"ts":"2026-06-05","kind":"sec.insider.m","reporter":"SHERWIN STEPHEN A","title":null,"shares":10000,"price_per_share":79.79,"usd_value":797900,"security_title":"Common Stock","importance":15.7979},{"ts":"2026-06-05","kind":"sec.insider.g","reporter":"Onyia Jude","title":"Chief Scientific Officer","shares":2441,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.s","reporter":"Norwalk Leslie V","title":null,"shares":1250,"price_per_share":168.0573,"usd_value":210072,"security_title":"Common Stock","importance":35.210071625},{"ts":"2026-06-02","kind":"sec.form144","reporter":"JULIE COOKE","title":"Officer","shares":36937,"usd_value":5946857,"security_title":"Common","approx_sale_date":"2026-06-02","accession_number":"0001950047-26-005514","importance":41.1893714},{"ts":"2026-06-02","kind":"sec.insider.s","reporter":"Cooke Julie","title":"Chief Human Resources Officer","shares":14214,"price_per_share":154.8252,"usd_value":2200685,"security_title":"Common Stock","importance":37.2006853928},{"ts":"2026-06-02","kind":"sec.insider.s","reporter":"Cooke Julie","title":"Chief Human Resources Officer","shares":9521,"price_per_share":157.6161,"usd_value":1500663,"security_title":"Common Stock","importance":36.5006628881},{"ts":"2026-06-02","kind":"sec.insider.s","reporter":"Cooke Julie","title":"Chief Human Resources Officer","shares":5466,"price_per_share":155.4566,"usd_value":849726,"security_title":"Common Stock","importance":35.8497257756},{"ts":"2026-06-02","kind":"sec.insider.s","reporter":"Cooke Julie","title":"Chief Human Resources Officer","shares":4216,"price_per_share":156.766,"usd_value":660925,"security_title":"Common Stock","importance":35.660925456},{"ts":"2026-06-02","kind":"sec.insider.s","reporter":"Cooke Julie","title":"Chief Human Resources Officer","shares":3520,"price_per_share":158.5897,"usd_value":558236,"security_title":"Common Stock","importance":35.558235744},{"ts":"2026-06-02","kind":"sec.insider.m","reporter":"Cooke Julie","title":"Chief Human Resources Officer","shares":24965,"price_per_share":81.49,"usd_value":2034398,"security_title":"Common Stock","importance":17.03439785},{"ts":"2026-06-02","kind":"sec.insider.f","reporter":"Keswani Sanjay Chandru","title":"Chief Medical Officer","shares":1733,"price_per_share":154.84,"usd_value":268338,"security_title":"Common Stock","importance":15.26833772},{"ts":"2026-06-02","kind":"sec.insider.m","reporter":"Keswani Sanjay Chandru","title":"Chief Medical Officer","shares":3212,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.form144","reporter":"JUDE ONYIA","title":"Officer","shares":11000,"usd_value":1741300,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001950047-26-005396","importance":40.34826},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Onyia Jude","title":"Chief Scientific Officer","shares":11000,"price_per_share":160.2464,"usd_value":1762710,"security_title":"Common Stock","importance":36.7627104},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Onyia Jude","title":"Chief Scientific Officer","shares":11000,"price_per_share":84.74,"usd_value":932140,"security_title":"Common Stock","importance":15.93214},{"ts":"2026-05-29","kind":"sec.insider.s","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":2261,"price_per_share":156.71,"usd_value":354321,"security_title":"Common Stock","importance":35.35432131},{"ts":"2026-05-29","kind":"sec.insider.m","reporter":"Delaet Ingrid","title":"Chief Regulatory Officer","shares":2261,"price_per_share":79.02,"usd_value":178664,"security_title":"Common Stock","importance":15.17866422},{"ts":"2026-05-21","kind":"sec.insider.m","reporter":"MORROW GEORGE J","title":null,"shares":3318,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"sec.insider.m","reporter":"SHERWIN STEPHEN A","title":null,"shares":3318,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"sec.insider.m","reporter":"LYONS GARY A","title":null,"shares":1659,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"sec.insider.m","reporter":"POPS RICHARD F","title":null,"shares":3318,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"sec.insider.m","reporter":"POON CHRISTINE A","title":null,"shares":3318,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"sec.insider.m","reporter":"RASTETTER WILLIAM H","title":null,"shares":3318,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"sec.insider.m","reporter":"Sharp Shalini","title":null,"shares":1659,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"sec.insider.m","reporter":"Norwalk Leslie V","title":null,"shares":1659,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"sec.insider.m","reporter":"Mercier Johanna","title":null,"shares":3318,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.s","reporter":"GORMAN KEVIN CHARLES","title":null,"shares":245088,"price_per_share":154.3318,"usd_value":37824872,"security_title":"Common Stock","importance":72.8248721984},{"ts":"2026-05-19","kind":"sec.form144","reporter":"KEVIN CHARLES GORMAN","title":"Director","shares":245088,"usd_value":38530284,"security_title":"Common","approx_sale_date":"2026-05-19","accession_number":"0001950047-26-004764","importance":47.706056896},{"ts":"2026-05-19","kind":"sec.insider.m","reporter":"GORMAN KEVIN CHARLES","title":null,"shares":205088,"price_per_share":43.24,"usd_value":8868005,"security_title":"Common Stock","importance":23.86800512},{"ts":"2026-05-18","kind":"sec.filing","form_type":"8-K","title":"8-K — NEUROCRINE BIOSCIENCES INC — 2026-05-18","url_slug":"/sec/cik-0000914475/8-k/0001193125-26-228013","accession_number":"0001193125-26-228013","importance":35},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Neurocrine Biosciences","title":"Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07227818","excerpt":"[\"Schizophrenia\"]","importance":60},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"POPS RICHARD F","title":null,"shares":15000,"price_per_share":157.6507,"usd_value":2364761,"security_title":"Common Stock","importance":37.3647605},{"ts":"2026-05-15","kind":"sec.insider.m","reporter":"POPS RICHARD F","title":null,"shares":15000,"price_per_share":47.89,"usd_value":718350,"security_title":"Common Stock","importance":15.718350000000001},{"ts":"2026-05-12","kind":"sec.form144","reporter":"Norwalk Leslie V","title":"Director","shares":6310,"usd_value":1028050,"security_title":"COMMON","approx_sale_date":"2026-05-12","accession_number":"0001949846-26-000269","importance":40.20561},{"ts":"2026-05-12","kind":"sec.insider.s","reporter":"Norwalk Leslie V","title":null,"shares":3810,"price_per_share":155.0134,"usd_value":590601,"security_title":"Common Stock","importance":35.590601054},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"Neurocrine Biosciences","title":"Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04490915","excerpt":"[\"Congenital Adrenal Hyperplasia\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Neurocrine Biosciences","title":"A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT07105111","excerpt":"[\"Schizophrenia\",\"Schizoaffective Disorder\",\"Bipolar Disorder\",\"Major Depressive Disorder\",\"Tardive Dyskinesia\"]","importance":25},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Neurocrine Biosciences","title":"Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT05206513","excerpt":"[\"Dyskinesia\",\"Cerebral Palsy\"]","importance":70},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Neurocrine Biosciences","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07536269","excerpt":"[\"Congenital Adrenal Hyperplasia\"]","importance":45},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"Neurocrine Biosciences","title":"NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06963021","excerpt":"[\"Major Depressive Disorder\"]","importance":60}]}